Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.71 |
| ▸ | RARG | P13631 | 9/20 | 0.71 |
| ▸ | RARA | P10276 | 6/20 | 0.71 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.71 |
| ▸ | RXRA | P19793 | 12/20 | 0.53 |
| ▸ | RXRB | P28702 | 11/20 | 0.53 |
| ▸ | RXRG | P48443 | 9/20 | 0.53 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19342945 | 0.86 | RARG (0.56) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL9268167 | 0.85 | CYP26A1 (0.57) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL5084210 | 0.85 | CYP3A4 (0.72) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL29353973 | 0.84 | RARB (1.00) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL3302926 | 0.84 | RARB (1.00) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342983 | 0.83 | CYP3A4 (0.59) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342961 | 0.83 | CYP3A4 (0.77) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342962 | 0.82 | RARB (0.48) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL31756569 | 0.81 | RARG (0.65) | RARBRARGRARACYP26A1CYP3A4 | |
| SCHEMBL19342946 | 0.81 | RARG (0.65) | RARBRARGRARACYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144783-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | UNIVERSITY OF DURHAM (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144783-A1 | SYNTHETIC RETINOIDS FOR USE IN RAR ACTIVATION | RARA, RXRA, RARB | RARB 3/4885RARG 4/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.